AB-19 (AUTOTAC Bio)

N/A

Report date: 2026/04/28 20:00:22

NME

Base Information

Drug NameAB-19 (AUTOTAC Bio)

Drug Alias NameAB-19 (AUTOTAC Bio)AB-19

ClassificationSmall molecules > Autophagy-Targeting Chimeras (AUTOTAC)

Mechanisms of ActionMicrotubule-associated protein tau inhibitors

TargetsMicrotubule-associated protein tau

Therapy Area/IndicationsSupranuclear Palsy, Progressive

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAutotac Bio Inc

China Registration ClassN/A

Active CompaniesAutotac Bio Inc

Inactive CompaniesN/A

Active IndicationsSupranuclear Palsy, Progressive

Inactive IndicationsN/A

ATC CodeN/A